Wouter Meuleman

Wouter Meuleman is a prominent figure in the field of computational biology and biotechnology. He currently serves as a Board Observer at Precede Biosciences, a company based in the San Francisco Bay Area.2

Professional Background

Meuleman's career is characterized by his expertise in computational biology and his focus on understanding the organization of the regulatory genome. His research aims to develop computational and machine learning approaches to analyze complex genome-wide maps of regulatory elements across various human cellular conditions.1

Academic Achievements::

• PhD in Computational Biology from Delft University of Technology and the Netherlands Cancer Institute (2012)
• MSc in Computer Science from Leiden University (2005)1

Career Highlights::

• Principal Investigator and Computational Biologist with independent NIH funding3
• Recipient of the NHGRI Genomic Innovator Award in 2020, providing flexible funding for a five-year period1
• Postdoctoral work at MIT and the Broad Institute1

Current Roles and Interests

Meuleman is actively involved in the biotechnology industry:

• Board Observer at Precede Biosciences2
• Previously served as an Entrepreneur In Residence at Illumina Ventures, focusing on companies in human therapeutics that leverage genomics technologies5
• Involved in seed funding and co-leading investments, such as the funding of Fluent BioSciences Inc., which was later acquired by Illumina4

Research Focus

Meuleman's long-term research goal is to make "augmented genomics" a reality. This new field aims to supplement the work of genome scientists with large-scale visualization and data-driven machine intelligence.1 His work involves developing computational methods to reduce the complexity of genome-wide regulatory element maps while retaining crucial information.

Wouter Meuleman's multifaceted career spans academia, research, and industry involvement, making him a notable figure in the intersection of computational biology, genomics, and biotechnology.